Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas

🔗 Access full article via NCI Cancer Currents

Vorasidenib inhibited the development of low-grade gliomas that had IDH1 orIDH2 gene mutations in a sizable clinical trial. The first targeted medication created specifically to treat brain tumors is called vorasidenib.